Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Saadettin Hulagu"'
Autor:
Ahmet Tarık Eminler, Cem Aygun, Tolga Konduk, Orhan Kocaman, Omer Senturk, Altay Celebi, Yesim Gurbuz, Saadettin Hulagu
Publikováno v:
Journal of Research in Medical Sciences, Vol 19, Iss 11, Pp 1058-1061 (2014)
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. It is generally accepted that insulin resistance is a pathophysiological factor in the development of NAFLD. In the present study, the aim
Externí odkaz:
https://doaj.org/article/4da71c5b67aa42199151af13a931b9e2
Publikováno v:
ESGE Days 2019.
Autor:
Zeynep Cantürk, Cem Aygun, Altay Celebi, Birsen Mutlu, Omer Senturk, Saadettin Hulagu, Suleyman Uraz, Tolga Konduk
Publikováno v:
European Journal of Gastroenterology & Hepatology. 18:175-180
Adiponectin is an adipose tissue-specific protein that has anti-inflammatory, antidiabetic and antiobesity effects. It has been suggested that adiponectin has a hepatoprotective role. Non-alcoholic fatty liver disease (NAFLD) is becoming more prevale
Autor:
Ugur Korkmaz, Saadettin Hulagu, Cengiz Erçin, Omer Senturk, Ali Erkan Duman, Ayşegül Tohumcu, Altay Celebi, Deniz Öğütmen Koç
Publikováno v:
The Turkish Journal of Gastroenterology. 24:192-194
Autor:
Abdurrahman Kadayifci, Mehmet Koruk, Nurdan Tözün, Aysun Bozbas, Suleyman Uraz, Saadettin Hulagu, Ilkay Simsek, Bulent Sivri, Mesut Akarsu, M. Cemil Savas
Publikováno v:
Current Medical Research and Opinion. 20:1301-1307
Recently, proton pump inhibitor (PPI)-based triple therapy has been recommended as a first line treatment in the eradication of Helicobacter pylori. The aim of this open, multicentre trial was to investigate the efficacy, safety, tolerability and the
Autor:
Meral Akdogan, Yucel Ustundag, Osman Özdoğan, Ilyas Tuncer, Hakan Yüceyar, Seyfettin Köklü, Ibrahim Dogan, Fatih Ozdener, Seda Erdoğan, Fatih Güzelbulut, Hüseyin Demirsoy, Abdülkadir Dökmeci, Mesut Akarsu, Ali Demir, Saadettin Hulagu
Background/Aims: To evaluate the association between insulin resistance and hepatic fibrosis in patients with chronic hepatitis C.Materials and Methods: A total of 104 chronic hepatitis C patients were included in this non-interventional, open-label,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66714a013359b0932190a4b302ffe189
https://hdl.handle.net/11454/15163
https://hdl.handle.net/11454/15163
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. It is generally accepted that insulin resistance is a pathophysiological factor in the development of NAFLD. In the present study, the aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______9534::ce989941b01099237ab805c9e21778d8
https://hdl.handle.net/20.500.12619/66699
https://hdl.handle.net/20.500.12619/66699
Autor:
Omer Senturk, Nadir Paksoy, Altay Celebi, Saadettin Hulagu, Nuh Zafer Cantürk, Cengiz Erçin, Zeynep Cantürk
Publikováno v:
Acta Cytologica. 44:1010-1014
OBJECTIVE: To evaluate which diagnostic test is preferable for the diagnosis of Helicobacter pylori in patients with gastroduodenal disease. STUDY DESIGN: H pylori infection was diagnosed prospectively in 101 patients. Diagnosis of H pylori was made
Autor:
Anthony Sebastian, Harlan I. Wright, Bakr Nour, Saadettin Hulagu, Ahmet Gurakar, David H. Van Thiel, B. Kerwin, Zeki Karasu, R McFadden, K. Stokes, A. Jazzar, Francis P. Cassidy
Publikováno v:
Digestive Diseases and Sciences. 45:1971-1976
Thrombocytopenia is a frequent complication of cirrhosis. Its pathogenesis is not well known, but it has been suggested that splenic congestion induced by portal hypertension may be a major contributory factor. However, the available data regarding t
Autor:
Sabite Kacar, Saadettin Hulagu, Serif Yilmaz, Bülent Kantarçeken, Murat Taner Gulsen, Nurdan Tözün, Alper Yurci, Kemal Mustafa Serez, Necati Yenice, Halil Ibrahim Bahcecioglu, Fahri Yakaryilmaz, Orhan Sezgin, Sait Bagci
Amaç: Pegile interferon alfa hepatit B tedavisinde kullanımı onaylanmış tek immunmodulator ilactır. Biz, bu calışmada kronik hepatit B’li hastalarda peginterferon alfa-2a (40KD) tedavisinin guvenilirli.ini de.erlendirdik. Gereç ve Yöntem:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c043e3eafd14ee4463c73a040768ea1
https://hdl.handle.net/20.500.12587/13300
https://hdl.handle.net/20.500.12587/13300